Rexulti vs Abilify: Uses, Side Effects, and Dosing

Rexulti and Abilify are related atypical antipsychotic medicines, but they are not interchangeable. Doctors distinguish them by the condition being treated, a person’s symptoms and medical history, other medicines, and the side effects most important to avoid or monitor.

Rexulti vs Abilify: side-by-side comparison

Rexulti and Abilify are prescription medicines in the atypical, or second-generation, antipsychotic class. Rexulti contains brexpiprazole and Abilify contains aripiprazole. Both influence dopamine and serotonin signaling in the brain, and both are sometimes used alongside an antidepressant for major depressive disorder. However, their approved indications, formulation options, side-effect profiles and treatment plans are not identical.

Feature	Rexulti (brexpiprazole)	Abilify (aripiprazole)
Medicine class	Atypical antipsychotic	Atypical antipsychotic
Common adult uses	Schizophrenia; add-on treatment for major depressive disorder; agitation associated with Alzheimer’s dementia in some settings	Schizophrenia; bipolar I disorder; add-on treatment for major depressive disorder; irritability associated with autism; Tourette’s disorder in pediatric patients, depending on local approval
How it is taken	Oral tablet	Oral tablets and other formulations in some regions, including long-acting injectable options
Possible notable effects	Weight gain, sleepiness, headache, restlessness and metabolic changes may occur	Restlessness or akathisia, insomnia or sleepiness, nausea, weight or metabolic changes, and impulse-control problems may occur
Key practical point	May be considered when its approved uses and individual tolerability fit the person’s needs	May be considered for a broader range of psychiatric conditions and where a suitable formulation is available

The table is a general guide rather than a self-treatment tool. Medicine approvals vary by country, and an individual’s response can differ substantially from average patterns. A clinician weighs expected benefit against safety considerations before recommending either option.

How clinicians tell Rexulti and Abilify apart

The first question is not which medicine is “better,” but what condition needs treatment. For example, Abilify may be considered in conditions such as bipolar I disorder or certain childhood neurodevelopmental conditions where it has an established role, while Rexulti may be considered for schizophrenia or as an adjunct to antidepressant treatment for depression. For a person with depression that has not improved enough with an antidepressant alone, the clinician also reviews previous treatment response and the nature of ongoing symptoms.

Clinicians then assess practical factors that can affect safety and adherence. These include age, pregnancy plans, heart and vascular history, diabetes risk, weight changes, sleep pattern, history of seizures, substance use, and any previous involuntary movements or severe medication reactions. They also ask about all prescription drugs, non-prescription medicines and supplements because interactions can change medicine levels or increase side effects.

Past experience with similar medicines is especially helpful. Someone who developed marked inner restlessness, known as akathisia, insomnia, excessive sleepiness, problematic weight gain, or impulse-control symptoms with one medicine may need a different approach. The prescriber may start gradually, arrange follow-up, and use symptom and side-effect changes over time to guide decisions rather than making assumptions from a diagnosis alone.

What each medicine may be used for

Rexulti may be prescribed for schizophrenia or as an add-on medicine for adults with major depressive disorder when an antidepressant alone has not provided sufficient improvement. In some locations, it is also approved for agitation associated with Alzheimer’s dementia. Agitation in dementia requires careful assessment because pain, infection, sleep disruption, medication effects and environmental stress can also contribute to changes in behavior.

Abilify may be used for schizophrenia, bipolar I disorder, and as adjunctive treatment for major depressive disorder. Depending on the person’s age and local approvals, it may also be used for irritability associated with autism or Tourette’s disorder. Some forms of aripiprazole are long-acting injections, which can be useful for selected people who prefer less frequent dosing or have difficulty taking a daily tablet. Injectable treatment is not appropriate for everyone and requires a planned clinical review.

For depression, either medicine is usually considered an augmentation strategy rather than a replacement for a comprehensive care plan. That plan may include psychotherapy, sleep support, physical health care, social support and review of antidepressant treatment. People seeking assessment for persistent low mood, loss of interest or related symptoms can learn more about depression and its evaluation.

Side effects, warnings and monitoring

Both medicines can cause side effects, although not everyone experiences them and their intensity varies. Possible effects include drowsiness or fatigue, dizziness, headache, nausea, constipation, restlessness, tremor, and changes in appetite or weight. Antipsychotic medicines can also affect blood sugar and cholesterol levels, so clinicians may monitor weight, blood pressure and relevant blood tests, particularly for people with diabetes or cardiovascular risk factors.

Akathisia can feel like an uncomfortable need to move, pacing, fidgeting, or an inability to sit still. It should be reported promptly, as it can be distressing and may be mistaken for worsening anxiety or agitation. Other movement-related effects, such as stiffness, tremor, slowed movement or involuntary facial and body movements, also need clinical review. Do not try to manage these effects by abruptly stopping the medicine.

Both medicines carry important warnings, including an increased risk of death in older adults with dementia-related psychosis. Antidepressant-related monitoring for new or worsening suicidal thoughts is also important, especially early in treatment or after a dose change. Aripiprazole has been associated with impulse-control problems in some people, such as new urges to gamble, shop, eat excessively or engage in sexual behavior that is difficult to control. Any new behavior of this kind should be discussed without shame or delay.

Rare but serious reactions can occur. High fever, severe muscle stiffness, confusion, heavy sweating, a very fast heartbeat, fainting, severe rash, swelling of the face or throat, or uncontrolled movements require urgent medical assessment. A clinician can also explain the role of psychiatric care in monitoring medicine safety and overall wellbeing.

Switching, taking medicines and daily self-care

Rexulti and Abilify should not be switched without a prescriber’s plan. Although they are related medicines, their doses cannot be compared tablet for tablet. A switch may involve gradual dose adjustment, overlap for a short time, or a different approach depending on the diagnosis, current dose, other medicines and prior side effects. Stopping suddenly can increase the chance of symptom return or uncomfortable discontinuation effects.

Taking the medicine at a consistent time each day, as prescribed, can make it easier to notice benefits and side effects. If a dose is missed, the person should follow the instructions provided by the prescriber or pharmacist rather than taking extra medicine. Alcohol and recreational drugs may worsen drowsiness, impair judgment, or complicate psychiatric symptoms, so discussing their use openly with the care team is important.

Simple tracking can improve a treatment review. Patients may note sleep, mood, energy, appetite, restlessness, unusual urges, hallucinations or mood elevation, and any physical symptoms. Family members or trusted supporters can sometimes notice changes that the patient does not recognize. Regular meals, activity suited to the person’s health, sleep routines and ongoing therapy can complement medication, but they do not replace prescribed treatment.

When to seek medical care

A prescriber should be contacted promptly if symptoms of depression, psychosis, mania, agitation or anxiety worsen after starting or changing either medicine. New severe restlessness, stiffness, tremor, significant sleep disruption, rapid weight change, high blood sugar symptoms, fainting, or new impulsive behavior also deserve timely review. The clinician may adjust the plan or investigate another cause.

Emergency help is needed for thoughts of self-harm or suicide, intent to harm others, severe confusion, inability to care for oneself, signs of a serious allergic reaction, or high fever with severe muscle stiffness and altered awareness. These symptoms should not be managed alone. A trusted person can help the individual access emergency services or the nearest emergency department.

For international patients, Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals can assess mental health conditions and coordinate individualized treatment plans. Ongoing care should remain connected to a qualified local clinician, especially when medicines require regular monitoring.

Questions to bring to a medication review

A useful medication discussion is specific and collaborative. Patients can ask which symptoms the medicine is intended to improve, how long it may take to assess benefit, what side effects are most relevant to their health history, and what monitoring is planned. They may also ask whether another diagnosis, medical condition or current medicine could be contributing to symptoms.

It can help to bring an up-to-date list of all medicines and supplements, previous medication experiences, and a brief record of symptoms. If pregnancy is possible or planned, this should be raised before starting, changing or stopping treatment. The safest choice between Rexulti and Abilify is the one made with a clinician who knows the person’s diagnosis, goals, health risks and response to care.

Frequently asked questions